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Aim: To test the effect of linagliptin in non-obese diabetic (NOD) mice, a murine model of type
1 diabetes, to unveil a possible direct cardiovascular action of dipeptidyl peptidase 4 (DPP-4)
inhibitors beyond glycaemia control.
Methods: NOD mice were grouped according to glycosuria levels as NODI: none; NODII: high;
NODIII: severe. Linagliptin treatment was initiated once they reached NODII levels. Vascular
reactivity was assessed ex vivo on aorta harvested from mice upon reaching NODIII level. In a
separate set of experiments, the effect of linagliptin was tested directly in vitro on vessels har-
vested from untreated NODIII, glucagon-like peptide-1 (GLP-1) receptor knockout and soluble
guanylyl cyclase-α1 knockout mice. Molecular and cellular studies were performed on endothe-
lial and endothelial nitric oxide synthase (eNOS)-transfected cells.
Results: In this ex vivo vascular study, endothelium-dependent vasorelaxation was ameliorated
and eNOS/nitric oxide (NO)/soluble guanylyl cyclase (sGC) signalling was enhanced. In the
in vitro vascular study, linagliptin exerted a direct vasodilating activity on vessels harvested
from both normo- or hyperglycaemic mice. The effect was independent from GLP-1/GLP-1
receptor (GLP-1R) interaction and required eNOS/NO/sGC pathway activation. Molecular
studies performed on endothelial cells show that linagliptin rescues eNOS from caveolin-1
(CAV-1)-binding in a calcium-independent manner.
Conclusion: Linagliptin, by interfering with the protein–protein interaction CAV-1/eNOS, led to
an increased eNOS availability, thus enhancing NO production. This mechanism accounts for
the vascular effect of linagliptin that is independent from glucose control and GLP-1/GLP-1R
interaction.
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1 | INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by
enteroendocrine cells in response to meals in order to reduce
postprandial hyperglycaemia.1,2 Dipeptidyl peptidase-4 (DPP-4) rapidly
inactivates incretins with a half-life of a few minutes3; therefore, DPP-
4 inhibitors or gliptin are currently used in the treatment of type 2 dia-
betes mellitus (T2DM). Recently, both experimental and clinical studies
have suggested that DPP-4 inhibitors can modulate cardiovascular
function4–7 by ameliorating ischaemia-reperfusion injury,8,9 reducing†These authors contributed equally to the study.
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the atherosclerotic lesions10 and vascular inﬂammatory reaction,11,12
and protecting the heart from acute myocardial ischaemia.7,13 There
are a number of underlying molecular mechanisms involved in angiopa-
thy associated with diabetes that are recognized, where there is
impaired nitric oxide (NO) bioavailability, to be the main cause of endo-
thelial dysfunction. It has been shown, in both preclinical14–17 and
clinical studies,18–21 that DPP-4 inhibitors positively modulate endo-
thelium function, but the molecular mechanism through which DPP-4
inhibitors exert this effect is still unknown. To date, both a GLP-1
receptor (GLP-1R)-dependent effect and the independent effect of
gliptins have been suggested. The GLP-1R-dependent hypothesis is
based on the ﬁnding that DPP-4 inhibition, by inducing an increase in
GLP-1, promotes its interaction with GLP-1R expressed in the endo-
thelium.22,23 This event activates a downstream signal transduction
that includes cAMP production and KATP channel activation.
24,25 The
receptor-independent hypothesis postulates a direct involvement of
DPP-4 in vascular reactivity. In line with this latter hypothesis, it has
been shown that DPP-4 is expressed in the vascular endothelium25
and its inhibition induces a direct vasorelaxant effect on isolated ves-
sels in vitro in the presence of GLP-1R antagonist.14,15
By overviewing the literature regarding the protective cardiovas-
cular effect of DPP-4 inhibitors, it appears evident that all the studies
have been performed in T2DM. This consideration highlights the dif-
ﬁculty in separating the beneﬁcial effect of DDP-4 inhibitors on car-
diovascular function aside from their action on glycaemia. In other
words, it is difﬁcult to exclude the hypothesis that the cardiovascular
effect of DPP-4 inhibitors is not secondary to their hypoglycaemic
action. To clarify this issue, we performed an experimental study in
which DPP-4 inhibitors were tested in a murine model of type 1 dia-
betes mellitus (T1DM), i.e. non-obese diabetic (NOD) mice. Because
of the lack of effect of this class of drugs on T1DM, this animal
model allowed us to dissect the DPP-4 inhibitors’ direct cardiovascu-
lar action from the indirect beneﬁcial effect attributable to the reduc-
tion in hyperglycaemia.
2 | MATERIALS AND METHODS
2.1 | Animals
All animal procedures were performed according to the Declaration
of Helsinki (European Union guidelines on use of animals in scientiﬁc
experiments) and the ARRIVE guidelines, and the study was author-
ized by the local animal care ofﬁce (Centro Servizi Veterinari, Univer-
sità degli Studi di Napoli “Federico II”). This work was carried out on
NOD/Ltj and age-matched CD-1 control mice (Charles River, Calco,
Italy). GLP-1R−/− and soluble guanylyl cyclase-α1 knockout (sGCα1−/−)
mice were also used and supplied by Boheringer Ingelheim
(Ingelheim, Germany) and Prof. P. Brouckaert from the University of
Ghent (Belgium), respectively. Mice were kept in an animal care facil-
ity under controlled temperature, humidity and light/dark cycle condi-
tions, with food and water ad libitum.
2.2 | NOD/Ltj mice
NOD/Ltj mice spontaneously develop T1DM,26 which was assessed
through measurement of glycosuria (monitored weekly) by using
glucose-6-oxidase-based assay (Biogamma, Roma, Italy). Mice were
divided into three groups based on glycosuria level (Figure 1A,B):
NODI: glycosuria <20 mg/dL = low/none; NODII: glycosuria 20-500
mg/dL = high; NODIII: glycosuria 500-1000 mg/dL = severe.
Oral treatment with linagliptin (0.3 and 1 mg/kg, daily) was
started when mice reached NODII stage. The mice were killed when
NODIII glycosuria level was achieved.
2.3 | Isolated organ bath studies
2.3.1 | Ex vivo
Once at NODIII level, mice treated with linagliptin as described
above, were sacriﬁced by exposure to CO2 and the aorta was rapidly
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FIGURE 1 A, Classiﬁcation of NOD mice based on
glycosuria and B, glycaemia value (n = 6-14;
*P < .05, **P < .01 vs 6 week; P < .05 vs NODII).
NODII mice (e.g. when glycaemia is already at
pathological concentration) were treated with
linagliptin (0.3 and 1 mg/kg) until they reached
NODIII stage. During the treatments, glycosuria
was monitored twice a week and mice were killed
when they reached NODIII stage. C, Effect of
linagliptin treatment (0.3, 1 mg/kg) on
acethylcholine-induced vasorelaxation in aortic
rings (n = 6 mice). D, Effect of linagliptin treatment
(0.3, 1 mg/kg) on isoprenaline-induced
vasorelaxation in aortic rings (n = 6 mice). Data are
presented as mean  s.e.m. ***P < .001 vs age-
matched control mice (normoglycaemic), and
P < .001 vs linagliptin vehicle (natrosol).
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dissected and cleaned from connective tissue. Aorta rings were cut,
mounted in an isolated organ bath ﬁlled with oxygenated Krebs solu-
tion at 37C, and connected to isometric transducers. Changes in ten-
sion were recorded continuously with a computerized system
(DataCapsule 17400; Ugo Basile, Comerio, Italy). Rings were initially
stretched until a resting tension of 1.5 g was reached and allowed to
equilibrate for 45 minutes. Concentration–response curves to acet-
hylcholine (acethylcholine) and isoprenaline (10 nM to 30 μM) were
performed on phenylephrine pre-contracted rings (1 μM).
2.3.2 | In vitro
Mice were killed by exposure to CO2 and aorta were rapidly har-
vested. We assessed concentration–response curves of linagliptin
and sitagliptin (100 nM to 30 μM) in the presence or absence of
endothelium and in the presence of N5-(1-Iminoethyl)-L-ornithine
dihydrochloride (L-NIO 10 μM, 15 minutes), 1H-[1,2,4]Oxadiazolo
[4,3-a]quinoxalin-1-one (ODQ 10 μM; 15 minutes) or vehicle.
2.4 | Cell culture experiments in a normal and
high-glucose environment
Human embryonic kidney cells stably transfected with eNOS (HEK-
293st) and bovine aortic endothelial cells (BAEC) were cultured and
grown in medium supplemented with 2 mmol/L glutamine, 10% heat-
inactivated fetal bovine serum, 50 U/mL penicillin/streptomycin.
HEK-293st were incubated with linagliptin (0.1-100 nM) or vehicle
[phosphate-buffered saline (PBS)] for 1 hour and then incubated for
2 hours in 25 mM (normal glucose) or 50 mM (high glucose) D-glucose
solution.27 Cells were then stimulated with calcium ionophore
A23187 (10 μM, 30 minutes). Cell pellets were collected and used
for Western blot analysis, while supernatants were used for nitrite/
nitrate (NOx) assay. The same protocol was applied in experiments
with BAEC.
2.5 | Immunoprecipitation study
Immunoprecipitation analysis was performed on BAEC (300 μg total
protein). Lysates were pre-cleared by incubating with protein A/G-
Agarose (SantaCruz Biotechnology, Hidelberg, Germany) for 1 hour at
4C and then incubated under agitation for 18 hours at 4C with the
relevant antibodies. Subsequently, samples were further incubated
for 1 hour at 4C with fresh beads, washed in PBS and collected by
centrifugation. Mouse monoclonal anti-eNOS (1:500, BD-Trasduction
Laboratories, Milano, Italy) and rabbit polyclonal anti-caveolin-1
(CAV-1, 1:1000, Santa Cruz Biotechnology) were used as primary
antibodies.
2.6 | Western blotting
Aorta or HEK-293st were homogenized in RIPA buffer. Denatured
proteins (40 μg) were separated on 10% sodium docecyl sulphate-
polyacrylamide gel. Membranes were blocked in PBS containing 0.1%
v/v Tween-20 and 3% w/v non-fat dry milk for 30 minutes, followed
by overnight incubation at 4C with rabbit polyclonal anti-CAV-1
(1:1000) or mouse monoclonal anti-eNOS (1:500). Membranes were
washed in PBST prior to incubation with horseradish-peroxidase-
conjugated secondary antibody for 2 hours. After incubation, mem-
branes were washed and developed using a chemiluminescence
assay. Images were obtained busing ImageQuant-400 (GE Healthcare,
Chicago, IL, USA). The housekeeping protein GAPDH (1:5000, Sigma-
Aldrich, Milan, Italy) was used for normalization.
2.7 | NOx assay
Assessment of NOx levels was performed according to Misko et al.28
with modiﬁcations. Brieﬂy, cellular supernatants (120 μL) were incu-
bated with cadmium (50 mg/well) in a microplate for 1 hour to con-
vert NO3
− into NO2
−. After centrifugation, total NOx content was
determined using a ﬂuorometric method29 and calculated against a
standard curve of sodium nitrite (50-2000 nM).
2.8 | Measurement of intracellular Ca+2
Changes in the intracellular Ca+2 concentration were measured in
BAEC using a Fluo-4 NW Calcium Assay Kit (Molecular Probes, Invi-
trogen, Carlsbad, California) according to the manufacturer’s instruc-
tions. Fluorescence (excitation 485 nm, emission 525 nm) was
measured for 3 minutes in a microplate ﬂuorometer (Promega, Madi-
son, WI, USA).
2.9 | Statistical analysis
All data were expressed as mean  standard error of the mean (s.e.
m.). Statistical analysis was performed using one-way analysis of vari-
ance (ANOVA), followed by Dunnett’s post-test, or two-way ANOVA
followed by Bonferroni’s post-test (GraphPad software, San Diego,
CA, USA). Differences with p values <.05 were taken to indicate sta-
tistical signiﬁcance.
3 | RESULTS
3.1 | Linagliptin treatment ameliorates
endothelium-dependent vasorelaxation in
NOD mice
We have previously shown that in NOD mice, the development of
T1DM is coupled with a progressive impairment of endothelium-
dependent vasorelaxation.27 Indeed, acethylcholine-induced vasore-
laxation is strongly blunted in NODIII mice, with a shift of the Emax
(maximal effect) from 85.3  3.6% in control mice to 29.8  5.0% in
NODIII. Similarly, isoprenaline-induced vasorelaxation results in
strongly impaired NODIII mice with a shift of the Emax from
72.5  6.3% in control mice to 26.6  3.3% in NODIII. In aorta rings
harvested after linagliptin treatment (0.3 and 1 mg/kg), both
acethylcholine- (Figure 1C) and isoprenaline- (Figure 1D) induced
vasorelaxation are improved, with a signiﬁcant increase in Emax
(50.7  5.03% and 56.3  5.4% for acethylcholine and isoprenaline,
respectively).
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3.2 | Linagliptin treatment enhances nitric oxide
signalling
Previously, we have shown that an increased expression of CAV-1
occurs in diabetes, contributing to reduced endothelium-dependent
vasodilatation.27 We therefore evaluated the effect of linagliptin
treatment on CAV-1 and eNOS expression. As shown in Figure 2A,B,
linagliptin modulates the expression of these two proteins towards a
more active state. Indeed, in aorta homogenates, eNOS analysis
shows a trend of enhanced expression after linagliptin treatment
(Figure 2A), as opposed to CAV-1, which shows a trend of reduced
expression (Figure 2B). These data, taken together, suggest that lina-
gliptin exerts a positive action on eNOS/NO signalling.
3.3 | eNOS/CAV-1 involvement in the linagliptin
effect in HEK-293 stably transfected with eNOS
(HEK-293st)
We have previously shown that a high-glucose environment blunts
eNOS activity27 (e.g. NO production) in HEK-293st (Figure 2C). This
effect correlates with increased CAV-1 expression, coupled with a
reduction in eNOS content (Figure 2D,E). Linagliptin incubation of
HEK-293st in a high-glucose environment (0.1-100 nM) completely
restores the physiological pattern observed in normoglycaemia.
Indeed, NO release showed a recovery trend, reaching statistical sig-
niﬁcance at the maximum concentration of 100 nM of linagliptin
(Figure 2C). This effect is accompanied by a signiﬁcant reduction in
CAV-1 expression (Figure 2D,E). Linagliptin (0.1-100 nM) exerts a
similar effect when tested on BAEC. Indeed, in BAEC placed in a
high-glucose environment, linagliptin restores nitrite levels observed
in normoglycaemia (Figure 5A).
3.4 | Linagliptin has a direct vasodilating activity
and acts through eNOS/cGMP signalling
As shown in Figure 3A, linagliptin can directly induce vasodilatation
in vitro in a concentration-dependent manner (100 nM to 30 μM)
on aorta harvested from control mice. Sitagliptin induces vasodilata-
tion as well, but is less active (Emax 39.4  7.3 % vs 89.4  2.7%,
sitagliptin vs linagliptin, respectively; Figure S1). As shown in
Figure 3A, in the absence of endothelium, linagliptin-induced vasodi-
latation is signiﬁcantly impaired. This result suggests that the endo-
thelium is the main player in linagliptin-induced vasodilatation.
Incubation of aorta rings with L-NIO, a selective eNOS inhibitor, sig-
niﬁcantly reduces linagliptin-induced vasorelaxation (Figure 3B). Sim-
ilarly, incubation with ODQ, an inhibitor of NO-dependent sGC
activity, signiﬁcantly inhibits linagliptin-induced vasorelaxation
(Figure 3B).
The same panel of in vitro experiments have been performed on
aorta harvested from mice with severe glycosuria, i.e. NODIII mice.
As shown in Figure 3C, linagliptin induces a concentration-dependent
vasodilatation in aortic rings of NODIII mice, although to a minor
extent compared with control mice. Similar to that which was
observed in control mice, when aortic rings are incubated with L-NIO
or ODQ, linagliptin-induced vasodilatation results signiﬁcantly
reduced (Figure 3D), conﬁrming the involvement of NO release in
linagliptin vasodilating action.
3.5 | Linagliptin-induced vasodilatation is
independent from GLP-1 receptor
To clarify the possible involvement of GLP-1R in linagliptin-induced
vasorelaxation, the same experimental protocol used for the in vitro
study was performed on aorta harvested from GLP-1R−/− mice and
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FIGURE 2 A,B, Representative western
blot images of eNOS and CAV-1 performed
on aorta homogenates harvested from
NODIII mice after treatment with linagliptin
(Lin; 1 mg/kg) in vivo. Data are compared
with NODIII mice treated with vehicle (n = 3
for each group). C, Effect of linagliptin (0.1,
10, 100 nM) on Ca2+ ionophore A23187-
induced NOx levels in HEK-293st in
hyperglycaemic condition (HG; n = 3 for
each group). HEK-293st treated with vehicle
in hyperglycaemic and normoglicaemic (NG)
conditions were used as controls. **P < .01
vs vehicle in the normoglycaemic condition
and P < .01 vs vehicle in the
hyperglycaemic condition. D,E,
Representative Western blot images of
eNOS and CAV-1 in HEK-293st in the
hyperglycaemic condition after treatment
with vehicle or linagliptin (100 nM); data are
compared with HEK-293st in the
normoglycaemic condition treated with
vehicle (n = 3 for each group). **P < .01 and
***P < .001 vs vehicle in the
normoglycaemic condition and P < .05 vs
vehicle in the hyperglycaemic condition.
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on their matched wild-type controls. Our results show that
linagliptin-induced vasodilatation is completely preserved in aortic
rings of GLP-1R−/− (Figure 4A). This evidence rules out GLP-1R
involvement from linagliptin-induced vasodilatation, reinforcing our
hypothesis of direct action of linagliptin on vascular function, inde-
pendent from GLP-1/GLP-1R interaction. L-NIO and ODQ signiﬁ-
cantly reduce linagliptin-induced vasodilatation also in GLP-1R−/−
mice (Figure 4B,C).
3.6 | Linagliptin fails to induce vasodilatation in
soluble guanylyl cyclase α1 knockout mice
To further validate the key role of NO in linagliptin-induced vasodila-
tation, we assessed the cumulative concentration–response curve on
aorta harvested from sGCα1
−/− mice.30,31 As shown in Figure 4D,
linagliptin-induced vasodilatation is signiﬁcantly impaired, conﬁrming
the involvement of the NO pathway and its downstream signalling in
linagliptin vasodilating action.
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FIGURE 3 A, Concentration–response curve of
linagliptin (0.1-30 μM) on aortic rings with or
without endothelium from control mice (n = 6 mice
for each group). **P < .01 and ***P < .001 vs
vehicle, P < .001 vs linagliptin. B, Effect of L-
NIO (10 μM) and of ODQ (10 μM) on linagliptin-
induced vasorelaxation on control mice (n = 6 mice
for each treatment). ***P < .001 vs vehicle. C,
Concentration–response curve of linagliptin (0.1-30
μM) on aortic rings harvested from NODIII mice.
Control mice were used as normoglycaemic control
(n = 6 mice). ***P < .001 vs control mice. D, Effect
of L-NIO (10 μM) and of ODQ (10 μM), on
linagliptin-induced vasorelaxation on NODIII mice
(n = 6 mice for each treatment). **P < .01 vs
vehicle. Data are presented as mean  s.e.m.
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FIGURE 4 A, Concentration–response curve of
linagliptin (0.1-10 μM) on aortic rings harvested
from GLP-1R−/− mice and respective wild-type
(WT) mice. B, Effect of L-NIO (10 μM) on
linagliptin-induced vasodilation in GLP-1R−/− and
WT mice. C, Effect of ODQ (10 μM) on linagliptin-
induced vasodilation in GLP-1R−/− and WT mice. D,
Concentration–response curve of linagliptin (0.1-10
μM) on aortic rings harvested from sGCα1−/− mice
compared with WT mice (n = 6 mice for each
group). ***P < .001 vs vehicle, P < .01 vs WT.
Data are presented as mean  s.e.m.
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3.7 | Linagliptin does not modify intracellular
Ca+2 inﬂux but interferes with the eNOS/CAV-1
complex in BAEC
To assess the role of [Ca+2]i in the linagliptin molecular effect, we
measured [Ca+2]i levels after linagliptin stimulation. When BAEC
were treated with linagliptin, no signiﬁcant rise in [Ca+2]i was
observed (Figure 5B). Bradykinin and A23187 were used as positive
controls. As shown in Figure 5C, in untreated cells, a protein band
immunoreactive to anti-eNOS antibody can be easily detected in
the CAV-1 immunoprecipitation. Treatment with linagliptin (10 and
100 nM) signiﬁcantly reduces the eNOS co-immunoprecipitation.
The effect is concentration-dependent; e.g. the highest concentra-
tion of linagliptin induced the lowest interaction between eNOS and
CAV-1.
4 | DISCUSSION
The concept that DPP-4 inhibitors could ameliorate vascular reactiv-
ity in diabetes has already been assessed in both clinical and experi-
mental studies.4–7,14–17 The selection of a T1DM animal model (NOD
mice) to investigate the vascular effect of DPP-4 inhibitors was based
on the ﬁnding that NOD mice: (1) spontaneously develop an autoim-
mune diabetes with remarkable analogy to human T1DM26,27; and
(2) develop a progressive impaired vascular reactivity, which we have
previously characterized.27 Taking advantage of the fact that DPP-4
inhibitors do not control glycaemia in T1DM, this strain represents an
appropriate tool with which to investigate the effect of DPP-4 inhibi-
tors on vascular complications, minimizing the confounding variable
attributable to the beneﬁcial effect that a reduction of glycaemia
would have by itself on vessels.
The impairment of NO-dependent vasodilation represents one of
the key events in the diabetes-induced vascular dysfunction in these
mice. Indeed, endothelium-dependent relaxation elicited by either
acethylcholine or isoprenaline are severely impaired in NODIII mice
and their endothelial-dependent effect is mediated by eNOS/NO/
sGC pathway activation.32–34 Treatment in vivo with linagliptin signiﬁ-
cantly improves the NO-dependent vasodilatation ex vivo, despite the
lack of control of glycaemia. In fact, as expected, the progressive,
age-related increase in glycosuria observed in NOD mice, was not
signiﬁcantly affected by linagliptin treatment. This ﬁnding raises the
possibility that DPP-4 inhibitors could have a direct effect on vessels.
It has been previously shown that DPP-4 inhibitors induce vasodilata-
tion on isolated rat15 and mouse aorta.14 In particular, Kroller-Schon
et al.15 have shown, that different DPP-4 inhibitors can directly dilate
the aorta in vitro, suggesting this “direct” effect is a class effect. To
deﬁne this issue, we switched from ex vivo to in vitro experiments.
Our in vitro experiments were designed to deﬁne the molecular
mechanism of DPP-4 inhibitor-induced vasodilatation and to compare
the DPP-4 inhibitor-induced vasodilatation in healthy and diabetic
conditions. The study was performed using sitagliptin, belonging to
the dipeptide mimetic structure subclass, and linagliptin, belonging to
the non-peptidomimetic DPP-4 sub-class. Linagliptin has a
concentration-dependent relaxation effect on healthy vessels, with a
Emax of almost 90%. Sitagliptin also has a relaxant effect but with an
Emax that is less than half that of linagliptin (Figure S1). The pharma-
cological modulation studies performed in vitro using linagliptin only,
because it induces the best vasodilatation, clearly showed that the
linagliptin effect involves eNOS/NO/sGC. Indeed, inhibition of either
eNOS or sGC leads to a signiﬁcant reduction of linagliptin-induced
vasorelaxation. One important issue is that the relaxant effect of lina-
gliptin is retained in the presence of dysfunctional endothelium,
e.g. in aorta harvested from NODIII mice. These data suggest that the
mechanism underlying the DPP-4 inhibitor effect is directed to the
eNOS/NO/sGC pathway. The involvement of the eNOS/NO path-
way in the linagliptin effect is further conﬁrmed by the ﬁnding that
linagliptin-induced vasodilatation in vitro is strongly impaired in the
aorta from sGCα1−/− mice. It is known that sGCα1β1 heterodimer is
the most abundant sGC isoform in the cardiovasculature,30 and mice
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lacking sGCα1−/− develop hypertension.31 These data, taken together
with the ﬁnding that DPP-4 inhibitor-induced vasorelaxation is com-
pletely preserved in GLP-1R−/− mice, show that the direct vasodilat-
ing effect of linagliptin is eNOS/NO/sGC-dependent and unrelated
to GLP-1/GLP-1R. The independence of the linagliptin vasoactive
effect from GLP-1R is also corroborated by other studies where its
beneﬁcial effect in stroke is also disjointed from GLP-1R activation.35
The hypothesis that DPP-4 inhibitors promote eNOS activation is
already present in the literature16,17; however, the molecular mechan-
ism is as yet not clear. Previously, we have shown that eNOS impair-
ment in NODIII mice vessels is attributable to an increased
expression of CAV-1, a resident caveolae protein that negatively reg-
ulates eNOS.27 Because both the ex vivo and the in vitro data pointed
to an effect on eNOS, we investigated the possibility that linagliptin
could interact with eNOS-CAV-1 complex. To this end, in a separate
set of experiments, aortas were harvested after in vivo linagliptin
treatment and molecular analysis was performed. The Western blot
analysis showed that eNOS tended to be upregulated, while CAV-1
had the opposite proﬁle, suggesting that more eNOS is in its active
state. To address this issue in depth, we used HEK-293 stably trans-
fected with eNOS. HEK-293st cells cultured in high glucose levels,
show an increase in CAV-1 expression coupled with reduced eNOS
expression. This pattern of expression correlates well with a reduc-
tion in NO levels.27 Linagliptin treatment signiﬁcantly inhibits CAV-1
expression, almost restoring it to normoglycaemic levels. All these
data point to CAV-1/eNOS complex disruption as the molecular
event responsible for the beneﬁcial vascular action of linagliptin. Our
next step, therefore, was to understand how linagliptin interferes
with the CAV-1/eNOS complex. Two possibilities were taken in con-
sideration. First, linagliptin interacts with the endothelial cellular
structure (i.e. membrane receptor or channel), acting as a calcium-
mobilizing agonist. This intracellular Ca2+ elevation augments calmod-
ulin afﬁnity to eNOS, leading to its activation.36,37 Second, linagliptin
directly interacts with the CAV-1/eNOS complex. The Fluo-4 assay
performed on BAEC clearly shows that linagliptin is not a calcium-
mobilizing agonist because no signiﬁcant rise in intracellular calcium
was observed after linagliptin stimulation. The CAV-1/eNOS immu-
noprecipitation study shows that linagliptin reduces the CAV-1/eNOS
interaction and this effect was concentration-dependent. Of particu-
lar relevance is the ﬁnding that the concentrations of linagliptin used
to achieve this effect in vitro, e.g. 10 nM, are within the range of lina-
gliptin circulating plasma levels in humans, making our data clinically
relevant.38
In conclusion, we show that the DPP-4 inhibitor linagliptin
improves vascular function in diabetes independently of glucose con-
trol, consistent with a recent paper showing a similar effect on cere-
brovascular circulation.39 This effect does not involve GLP-1 but
relies on direct interaction of linagliptin with the eNOS/CAV-1 com-
plex, leading to a rescue of eNOS activity from the negative regula-
tion operated by CAV-1. This molecular event, in turn, causes an
increase in NO production with a signiﬁcant beneﬁcial effect on vas-
cular function. One possible clinical implication is that the therapeutic
use of linagliptin could also be associated with a protective effect on
the vascular dysfunction associated with endothelial impairment in
patients with T2DM; however, this possibility, even though it has
been already put forward in the current literature, needs an appropri-
ate clinical study.
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